Research interests My research interests are the pathology and treatment of cardiovascular and pulmonary vascular diseases. The MRC ILA Heart study was the first randomised study to demonstrate the therapeutic tractability of inflammatory signalling in coronary artery disease. Findings were published in the European Heart Journal and the New England Journal of Medicine and validated by CANTOS, a phase III study of the interleukin-1 beta targeted therapy Canakinumab that demonstrated a reduction in recurrent cardiac events. My current work focuses on the pathology of pulmonary arterial hypertension and the development of novel therapeutic strategies. Recent pre-clinical studies have led to early phase clinical studies of pulmonary artery denervation, implantable pulmonary artery pressure monitors and new drug studies.